Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | ESR1 | P03372 | 10/20 | 0.35 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.34 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | TSPO | P30536 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24682181 | 1.00 | MAOB (0.40) | MAOBESR1BDKRB1RIPK1TAS2R14 | |
| SCHEMBL24682969 | 0.89 | MAOB (0.39) | MAOBESR1BDKRB1ESR2TSPO | |
| SCHEMBL30701683 | 0.89 | MAOB (0.39) | MAOBESR1BDKRB1ESR2TSPO | |
| SCHEMBL29799890 | 0.87 | ESR1 (0.39) | MAOBESR1ESR2MAPK14 | |
| SCHEMBL24683210 | 0.87 | ESR1 (0.39) | MAOBESR1ESR2MAPK14 | |
| SCHEMBL24682825 | 0.84 | MAOB (0.40) | MAOBESR1RIPK1TAS2R14ESR2 | |
| SCHEMBL29799932 | 0.84 | MAOB (0.40) | MAOBESR1RIPK1TAS2R14ESR2 | |
| SCHEMBL24683213 | 0.82 | MAOB (0.40) | MAOBESR1ESR2TSPO | |
| SCHEMBL29799904 | 0.82 | MAOB (0.40) | MAOBESR1ESR2TSPO | |
| SCHEMBL24683874 | 0.82 | HSP90AA1 (0.35) | MAOBBDKRB1RIPK1MAPK14TSPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174629-A1 | 2-ACETAMIDO-6-HYDROXY-BENZOTHIOPHENE DERIVATIVES WITH ANTIVIRAL ACTIVITY | OTCPHARM JSC (RU) | 2024-05-30 | — | — | US | disclosed |
| EP-4293017-A1 | 2-ACETAMIDO-6-HYDROXY-BENZOTHIOPHENE DERIVATIVES WITH ANTIVIRAL ACTIVITY | Otcpharm JSC (RU) | 2023-12-20 | — | — | EP | disclosed |
| CN-117222630-A | 2-acetamido-6-hydroxy-benzothiophene derivatives having antiviral activity | OTC制药公司(JSC) | 2023-12-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174629-A1 | 2-ACETAMIDO-6-HYDROXY-BENZOTHIOPHENE DERIVATIVES WITH ANTIVIRAL ACTIVITY | ACE2, ACE, EIF2AK2 | MAOB 707/4885ESR1 4305/4885BDKRB1 3575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.